Acadia Jumps After Highlighting Nuplazid Opportunity In PDP Treatment

Shares of Acadia (ACAD), a biopharmaceutical company focused on central nervous system disorders, are rising after its presentation at the JP Morgan Healthcare Conference Wednesday night.

SIGNIFICANT COMMERCIAL OPPORTUNITY FOR NUPLAZID: Nuplazid is a selective serotonin inverse agonist/antagonist, or SSIA, used to treat Parkinson's disease psychosis. During the JP Morgan conference, Acadia said it anticipated 2018 Nuplazid revenue of $220M-$225M, with Q3 Nuplazid revenue of $58.3M, representing 64% growth year-over-year. With the company's launch of a 34 milligram capsule of Nuplazid in Q3, Acadia CEO Steve Davis said: "We think with the new drug approved and as patients get more and more experience with a very favorable tolerability profile and the strong efficacy that we have that we'll be able to grow that market and physicians will likely begin treating earlier in the treatment paradigm". 

PRICE ACTION: Shares of Acadia are up approximately 5.8% to $20.89 in afternoon trading.

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.